Abstract: A nucleic acid encodes a single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of ?-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.
Type:
Grant
Filed:
March 27, 2019
Date of Patent:
March 3, 2020
Assignee:
The Government of the United States of America, as represented by the Secretary of the Navy
Inventors:
Daniel Zabetakis, George P. Anderson, Ellen R. Goldman, Kendrick Turner, P. Audrey Brozozog Lee
Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
February 25, 2020
Assignee:
Trellis Bioscience, LLC
Inventors:
Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
Abstract: The present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a Gram-negative or Gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample.
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
February 18, 2020
Assignee:
UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
Inventors:
Matthias Eberl, Nicholas Topley, Chan-yu Lin
Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
Type:
Grant
Filed:
August 3, 2016
Date of Patent:
February 4, 2020
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
February 4, 2020
Assignee:
SCANDINAVIAN BIOPHARMA HOLDING AB
Inventors:
Ann-Mari Svennerholm, Joshua Tobias, Nils Carlin, Jan Holmgren
Abstract: An isolated antibody, consisting of an anti-glutathionylated eNOS antibody, wherein the anti-glutathionylated eNOS antibody has been generated against an immunogen consisting of a peptide that includes glutathione; a first linker; an eNOS peptide; a second linker; and a T-cell epitope; and wherein the anti-glutathionylated eNOS antibody is adapted to recognize redox modulated eNOS proteins.
Abstract: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.
Abstract: Probiotics and ways to increase their effectiveness are provided. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.
Abstract: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful for inducing immunity to Escherichia coli pathogenic bacteria. The methods provide for the induction of B-cell mediated immunity and for the induction of antibody capable of inhibiting the adherence and colonization of Escherichia coli, including enterotoxigenic Escherichia coli, to human cells.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
December 10, 2019
Assignee:
The United States of America as represented by the secretary of the navy
Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
November 26, 2019
Assignee:
Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre
Inventors:
Hester Jeanette Bootsma, Pieter Jan Burghout, Peter Wilhelmus Maria Hermans, Johanna Jacoba Elisabeth Bijlsma, Oscar Paul Kuipers, Tomas Gerrit Kloosterman
Abstract: In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens ?-toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
October 22, 2019
Assignees:
Arkion Life Sciences, LLC, United Sates of America, as Represented by the Secretary of Agriculture
Inventors:
Hyun S. Lillehoj, Earnest W. Porta, Samuel V. Walker, Leslie A. Confer, Ujvala Deepthi Gadde, Cyril Gay
Abstract: A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
September 17, 2019
Assignee:
Scandinavian Biopharma Holding AB
Inventors:
Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
Abstract: Described herein are improved diagnostic tools for veterinary and human use which can be used for serodiagnosing A. platys in mammals, particularly in members of the Canidae family and in humans. The diagnostic tools are a group of outer membrane proteins of A. platys and variants thereof, referred to hereinafter as the “OMP proteins”, a group of outer membrane proteins of A. platys and variants thereof referred to hereinafter as the “P44 proteins”, and antibodies to the OMP proteins and the P44 proteins.
Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
August 6, 2019
Assignee:
MedImmune Limited
Inventors:
Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
July 30, 2019
Assignee:
SNIPR Technologies Limited
Inventors:
Jasper Clube, Morten Sommer, Christian Grøndahl
Abstract: The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.
Type:
Grant
Filed:
February 5, 2016
Date of Patent:
July 30, 2019
Assignee:
BOEHRINGER INGELHEIM ANIMAL HEATLH USA INC.
Inventors:
Laurent Bernard Fischer, Nicolas Pierre Yves Carboulec, Fabien Lux
Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.
Type:
Grant
Filed:
February 3, 2016
Date of Patent:
May 28, 2019
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Inventors:
John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.